FindTrial
Sign In

An Open-Label Extension Study to Evaluate Safety and Tolerability of Multiple Subcutaneous Doses of LY2439821 in Japanese Patients with Rheumatoid Arthritis on Concomitant Methotrexate

An Open-Label Extension Study to Evaluate Safety and Tolerability of Multiple Subcutaneous Doses of LY2439821 in Japanese Patients with Rheumatoid Arthritis on Concomitant Methotrexate

Status
Unknown
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221280
Enrollment
Unknown
Registered
2010-10-22
Start date
2010-10-22
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

investigational material(s) Generic name etc : LY2439821 INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigat

Sponsors

Eli Lilly Japan K.K.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Have received 7 injections of LY2439821 subcutaneously and completed the follow-up period (14 weeks) in Study I1F-JE-RHAL 30mg/80mg/180mg cohort. Have received 11 injections of LY2439821 subcutaneously and completed the follow-up period (14 weeks) in Study I1F-JE-RHAL 240/120mg cohort.

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026